US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Diamyd Medical's Phase II study in cancer pain fully recruited

The last study participant has been recruited to Diamyd Medical’s Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.The purpose of the Phase II study is to evaluate NP2 Enkephalin for the treatment of severe and chronic cancer pain. It is the first sizeable and placebo-controlled clinical trial of a drug candidate based on Diamyd Medical’s patented Nerve Targeting Drug Delivery System, a unique technology for delivery of therapeutics directly to the nervous

Prevention study with Diamyd´s diabetes vaccine fully recruited

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical’s diabetes vaccine Diamyd®. The study is thus fully recruited. The purpose of the study is to evaluate whether preventive treatment with Diamyd® can delay or halt the progression of the disease so that the children do not develop clinical symptoms of type 1 diabetes.The children enrolled in the study are healthy, but have all been found to have an ongoing autoimmune process, where their blood sugar-regulating

Diamyd’s European Phase III study fully recruited

Diamyd Medical announces today that the company’s European Phase III study of the diabetes vaccine Diamyd® is now fully recruited. It is estimated that results from the study can be reported during spring 2011.320 children and adolescents between 10 and 20 years of age and recently diagnosed with type 1 diabetes have now been identified and included in the company’s European Phase III study and have received their first injection of the Diamyd® vaccine or placebo. The study is thus fully recruited. “It is clear now that we will be able to present results from the study during spring 2011

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media